News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

LAM Pharmaceutical Corporation (LAMP) Distribution Network Expands In China

10/19/2005 5:12:40 PM

LEWISTON, N.Y., Feb. 10 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that its distribution partner, Sinopharm Group, reported establishing a solid foothold throughout the entire eastern part China. Marketing and sales programs are now underway in 10 provinces including Beijing, Guangdong, Shanghai, Yunnan, Henan, Shandong, Shanxi, Hebei, Tianjin and Sichuan.

Mr. Dongze Huangfu, a senior executive within Sinopharm's distribution network, remarked, "Our efforts are focused on some of the most populous and affluent provinces in China. In terms of actual numbers, we are now marketing LAM IPM Wound Gel to a marketplace with over 540.0 million people or over 40% over the total population of China. Also included in this territory are China's three largest cities."

Mr. Huangfu concluded, "We are very pleased with our results to date. It is very rewarding for all of us to be marketing a product as efficacious as the LAM IPM Wound Gel."

Mr. Joseph Slechta, President and Chief Executive Officer of LAM Pharmaceutical, remarked, "We are understandably delighted about the progress of our Chinese distribution partners. Our joint marketing efforts and teamwork will continue to bring new successes in this dynamic market."

About LAM Pharmaceutical, Corp.

L.A.M. Pharmaceutical, Corp., , is a biomedical company with offices in Lewiston, New York, Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.

About Sinopharm Foreign Trade Ltd.

Sinopharm Foreign Trade, Ltd., , a wholly owned subsidiary of China National Pharmaceutical Group Corp., was established in 1998 to deal in both Chinese and western pharmaceutical products, medical devices and pharmaceutical and chemical materials.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

Stephanie Carrington (Investors/Media) 646-536-7017 The Ruth Group

Web sites:

LAM Pharmaceutical, Corp.

CONTACT: Investors and Media - Stephanie Carrington, +1-646-536-7017,of The Ruth Group for LAM Pharmaceutical, Corp.

Read at

comments powered by Disqus